marked.bio

EGFR ADC · ADC

SYS6010

5 active trials, targeting EGFR. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 5 5 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of SYS6010.

  1. CSPC 4
  2. Conjupro Biotherapeutics 1

Trials

5 of 5 trials shown

  1. A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

    Not yet recruiting Phase 3 CSPC Started 2026Primary completion 2026-12 NCT07376382

    SYS6010osimertinib FDA EUpemetrexed

    Carry at least one EGFR-sensitive mutation (ex19del or L858R, which can be combined with other EGFR mutations).

    EGFR exon 19 deletion / L858RNSCLC

  2. SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

    Not yet recruiting Phase 3 CSPC Started 2026Primary completion 2027-12 NCT07442565

    SYS6010docetaxel

    EGFR mutations (currently approved by regulatory authorities for targeted therapy) must be confirmed neg…

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  3. Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

    Recruiting Phase 3 CSPC Started 2025Primary completion 2026-07 NCT06927986

    SYS6010pemetrexedcisplatincarboplatin

    Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

    EGFR exon 19 deletion / L858REGFR-mutated Locally Advanced or Metastatic NSCLC

  4. A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

    Not yet recruiting Phase 2 CSPC Started 2025Primary completion 2026-11 NCT07256509

    SYS6010osimertinib FDA EUpemetrexedcisplatincarboplatin

    …mbined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  5. A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 Conjupro Biotherapeutics Started 2023Primary completion 2027-05 NCT05948865

    SYS6010

    In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) sugges…

    EGFR exon 19 deletion / L858RCancer, Cancer, Lung